Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, Margit N. Horiba, Sreenivasa R. Nattam, Robert Marsh, James Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Cohen, James Wade, Bethany Sleckman, Heinz Josef Lenz, Patrick Stiff, Pankaj Kumar, Peng Xu, Les Henderson, Naoko Takebe, Ravi SalgiaXi Wang, Walter M. Stadler, Frederic J. De Sauvage, Hedy L. Kindler

Research output: Contribution to journal › Article › peer-review

423 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences